Jane Street’s Catalyst Pharmaceutical CPRX Stock Holding History

Jane Street’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$651K	Buy	+26,300	New	+$627K	﹤0.01%	7421
2025 Q2	–	Sell	-15,800	Closed	-$383K	–	9780
2025 Q1	$383K	Buy	+15,800	New	+$356K	﹤0.01%	7373
2023 Q4	–	Sell	-31,700	Closed	-$371K	–	9246
2023 Q3	$371K	Buy	31,700 +13,500	+74%	+$181K	﹤0.01%	6726
2023 Q2	$245K	Sell	18,200 -673,800	-97%	-$9.7M	﹤0.01%	7416
2023 Q1	$11.5M	Buy	692,000 +651,900	+1,626%	+$10.8M	﹤0.01%	1502
2022 Q4	$746K	Sell	40,100 -38,900	-49%	-$599K	﹤0.01%	5477
2022 Q3	$1.01M	Buy	79,000 +56,400	+250%	+$668K	﹤0.01%	5385
2022 Q2	$158K	Sell	22,600 -4,900	-18%	-$35.9K	﹤0.01%	8377
2022 Q1	$228K	Buy	+27,500	New	+$194K	﹤0.01%	8838
2021 Q3	–	Sell	-47,400	Closed	-$273K	–	10003
2021 Q2	$273K	Buy	+47,400	New	+$245K	﹤0.01%	8314

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Jane Street's CPRX Position: Q1 2026 in Review

Jane Street increased its Catalyst Pharmaceutical (CPRX) stake by 105% in Q1 2026, buying an estimated $6.65M and bringing the position to 545,227 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Jane Street first reported a position in CPRX in Q3 2013 and has held it in 30 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Jane Street held 545,227 shares of Catalyst Pharmaceutical worth $13.5M as of Q1 2026.
Jane Street bought 278,974 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.65M.
Catalyst Pharmaceutical made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2175 holding.
Jane Street first reported a position in Catalyst Pharmaceutical in Q3 2013 and has held it in 30 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.